SACC has recently entered into a partnership and launched a co_operation with HYD LLC for Cancer Research and Drug Development and its owner, who is also a scientist and researcher with Mr.Gábor Somlyai.
Dr Gábor Somlyai PhD is a Hungarian biologist, worked in the field of genetic engineering and gene mapping in Hungary, at the Georg-August University in Göttingen (Germany) and as a postdoctoral fellowship at the University of Missouri (Columbia, Missouri, USA). In the wake of the Hungarian Nobel-prize winning scientist Albert Szent-Györgyi - who said that the true cause of cancer should be looked for at the submolecular level - dr. Somlyai began his investigations in 1990 at the Hungarian Institute of Oncology, examining the biological importance of naturally occurring deuterium. HYD LLC. for Cancer Research and Drug Development was established in 1993 for the development and worldwide marketing of drugs and consumer products primarily for the prevention and treatment of various kinds of cancer, that utilize the novel proprietary procedure, deuterium depletion. Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and to influence other physiological processes offering a completely safe, non-invasive at the same time a highly effective treatment modality. Drug development based on deuterium depletion may get an important role in present-day drug research, and in medical science of the future. The scientific model harmonizes the results of modern science in the last decades with pure biochemical research of nearly hundred years in a unique way, opening the way to more successful treatment off first of all malignant and metabolic diseases.Gábor Somlyai is a Hungarian biologist, worked in the field of genetic engineering and gene mapping in Hungary, at the Georg-August University in Göttingen (Germany) and as a postdoctoral fellowship at the University of Missouri (Columbia, Missouri, USA).

In the wake of the Hungarian Nobel-prize winning scientist Albert Szent-Györgyi - who said that the true cause of cancer should be looked for at the submolecular level - dr. Somlyai began his investigations in 1990 at the Hungarian Institute of Oncology, examining the biological importance of naturally occurring deuterium. HYD LLC. for Cancer Research and Drug Development was established in 1993 for the development and worldwide marketing of drugs and consumer products primarily for the prevention and treatment of various kinds of cancer, that utilize the novel proprietary procedure, deuterium depletion. Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and to influence other physiological processes offering a completely safe, non-invasive at the same time a highly effective treatment modality. Drug development based on deuterium depletion may get an important role in present-day drug research, and in medical science of the future. The scientific model harmonizes the results of modern science in the last decades with pure biochemical research of nearly hundred years in a unique way, opening the way to more successful treatment off first of all malignant and metabolic diseases.

Gábor Somlyai is a Hungarian biologist, worked in the field of genetic
engineering and gene mapping in Hungary, at the Georg-August University
in Göttingen (Germany) and as a postdoctoral fellowship at the
University of Missouri (Columbia, Missouri, USA). In the wake of the
Hungarian Nobel-prize winning scientist Albert Szent-Györgyi - who said
that the true cause of cancer should be looked for at the submolecular
level - dr. Somlyai began his investigations in 1990 at the Hungarian
Institute of Oncology, examining the biological importance of naturally
occurring deuterium. HYD LLC. for Cancer Research and Drug Development
was established in 1993 for the development and worldwide marketing of
drugs and consumer products primarily for the prevention and treatment
of various kinds of cancer, that utilize the novel proprietary
procedure, deuterium depletion. Deuterium depletion is a completely
original approach to inhibit the growth of cancer cells in the body and
to influence other physiological processes offering a completely safe,
non-invasive at the same time a highly effective treatment modality.
Drug development based on deuterium depletion may get an important role
in present-day drug research, and in medical science of the future. The
scientific model harmonizes the results of modern science in the last
decades with pure biochemical research of nearly hundred years in a
unique way, opening the way to more successful treatment off first of
all malignant and metabolic diseases.